7d
Hosted on MSNGSK’s Penmenvy meningococcal vaccine gains FDA approvalThe studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years.
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...
UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal ...
葛兰素史克公司 (LSE/NYSE: GSK) 宣布,美国食品药品监督管理局 (FDA) 已批准 PENMENVY(脑膜炎球菌 A、B、C、W 和 Y 组疫苗)供 10 至 25 岁人群使用。该疫苗针对通常导致侵袭性脑膜炎球菌病 (IMD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results